The overall goal of the Cell Therapies Core (CTC) is to provide service to members to facilitate translation of promising therapies for patients with cancer. The CTC manufactures cellular products in support of novel, investigator-initiated clinical studies, while maintaining compliance with standards set by the U.S. Food and Drug Administration (FDA) and other accrediting bodies. To accomplish this goal, the CTC's Specific Aims are to: 1) Develop new technologies for translation of cellular therapies 2) Provide regulatory assistance in support of cellular therapies 3) Educate and train scientists and clinicians committed to careers in cellular therapies 4) Produce the highest quality cellular products for immunotherapy clinical trials The CTC works with members through all stages of a clinical trial, including collaboration during pre-clinical planning. The CTC technical director, manager, and quality staff assist with preparation of protocols, funding/grant applications, INDs, and other regulatory submissions. Once the cellular therapy agent under study is administered to the patient, the CTC analytic laboratory may continue to assist in post-treatment immune monitoring or, when desired by investigators, may directly conduct the immune monitoring studies. The CTC has four key areas of activity: 1. New product development, wherein new cell therapy products undergo pre-clinical scale-up, testing, and validation 2. Cell collection and cryostorage to obtain mononuclear cells, lymphocytes, and antigen presenting cells for production of cell therapy products and immune monitoring studies 3. Cell therapy product manufacturing, including dendritic and tumor cell-based gene-modified and un- modified vaccines and purification and/or expansion of T lymphocytes (T regulatory cells, tumor infiltrating lymphocytes, tumor antigen-associated T cells, chimeric antigen receptor T cells) 4. An analytic laboratory that performs the dual functions of product quality testing and post-treatment immune monitoring During the project period, the CTC supported 19 cancer center investigators involved in 27 projects and 39 publications. In FY2015, the CTC supported 15 projects, of which 87% represented member projects and 55% of total usage supported peer-review-funded members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-21
Application #
9637347
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
21
Fiscal Year
2019
Total Cost
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Gonzalez, Brian D; Hoogland, Aasha I; Kasting, Monica L et al. (2018) Psychosocial impact of BRCA testing in young Black breast cancer survivors. Psychooncology 27:2778-2785
Akuffo, Afua A; Alontaga, Aileen Y; Metcalf, Rainer et al. (2018) Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem 293:6187-6200
Mahajan, Nupam P; Coppola, Domenico; Kim, Jongphil et al. (2018) Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells. Sci Rep 8:1954
Rounbehler, Robert J; Berglund, Anders E; Gerke, Travis et al. (2018) Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:1376-1383
Christy, Shannon M; Schmidt, Alyssa; Wang, Hsiao-Lan et al. (2018) Understanding Cancer Worry Among Patients in a Community Clinic-Based Colorectal Cancer Screening Intervention Study. Nurs Res 67:275-285
Chang, James M; Kosiorek, Heidi E; Dueck, Amylou C et al. (2018) Stratifying SLN incidence in intermediate thickness melanoma patients. Am J Surg 215:699-706
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Porubsky, Caitlin; Teer, Jamie K; Zhang, Yonghong et al. (2018) Genomic analysis of a case of agminated Spitz nevi and congenital-pattern nevi arising in extensive nevus spilus. J Cutan Pathol 45:180-183
Zhu, Genyuan; Nemoto, Satoshi; Mailloux, Adam W et al. (2018) Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line. Front Immunol 9:1609

Showing the most recent 10 out of 1254 publications